{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    65
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose of study drug"
      },
      {
        "id": "anchor_llm_1",
        "definition": "The start of the screening/observation period, with Day 1 implicitly following the Day -42 to Day -1 window",
        "anchorType": "Day1",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening/observation period (Day -42 to Day -1)"
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "baseline visit"
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_25",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_interval_2",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_4",
        "type": "Interval",
        "sourceText": "PK samples at "
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P42D",
        "endOffset": "-P1D",
        "sourceText": "Day -42 to Day -1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P42D",
        "endOffset": "-P1D",
        "sourceText": "Days -42 through Day -1"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "endOffset": "P175D",
        "sourceText": "Day 0 through Day 175"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P25D",
        "sourceText": "Weeks 1-25"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P5D",
        "endOffset": "P26D",
        "sourceText": "Week 5 through Week 26"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "treatment \nperiod"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "dosing window"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "Treatment period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "observation period"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "Observation Period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "1 hour post"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "1 hour after"
      },
      {
        "id": "rep_llm_1",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P1Y",
        "interval": "P3M",
        "minObservations": 4,
        "exitCondition": "Completion of 1st year of treatment in Part B",
        "sourceText": "Samples will be collected at 3-month intervals during the 1st year of treatment in Part B"
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P1Y",
        "endOffset": "P2Y",
        "interval": "P6M",
        "minObservations": 2,
        "exitCondition": "Remainder of the time on study",
        "sourceText": "then at 6-month intervals for the remainder of the time on study."
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "PT0H",
        "endOffset": "PT1H",
        "interval": "PT1H",
        "minObservations": 2,
        "exitCondition": "null",
        "sourceText": "Collection of PK samples at predose and 1 hour (±15 minutes) postdose was added."
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "PT0H",
        "endOffset": "PT24H",
        "interval": "PT24H",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "safety assessments include AEs with onset within 24 hours of infusion was added."
      },
      {
        "id": "rep_llm_5",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P2Y",
        "interval": "P2Y",
        "minObservations": 1,
        "exitCondition": "24 months following LPO for Part A",
        "sourceText": "The Part B open-label extension study will run for 2 years instead of 1 year following last patient out (LPO) under Part A."
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4",
          "epoch_5"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Baseline",
          "Part B Year 1 (3-month intervals)",
          "End of Study",
          "Part A Completion",
          "Screening",
          "Part B Year 2 (6-month intervals)",
          "Day 1",
          "End of Study (24 months post-Part A LPO)"
        ],
        "sourceText": "[{'condition': 'Subject at preselected site/country qualifies for home infusion', 'path': ['HOME_INFUSION_QUALIFICATION', 'HOME_INFUSION_ADMINISTRATION', 'SATISFACTION_ASSESSMENT']}, {'condition': 'Immunogenicity monitoring requires follow-up', 'path': ['ADA_TESTING', 'PREDOSE_PD_BACKUP_SAMPLING']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 7; RECURRING signals: 2"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Laboratory Test",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Window",
        "rationale": "WINDOW signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Window",
        "rationale": "WINDOW signals: 4"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 7"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "ADA sample collection (Part B)",
        "executionType": "Single",
        "rationale": "Samples are collected at scheduled intervals during the 1st year and then every 6 months."
      },
      {
        "activityId": "Satisfaction with home infusion",
        "executionType": "Single",
        "rationale": "Assessment occurs at two specific scheduled points: after the first home infusion and after the fourth home infusion."
      },
      {
        "activityId": "SLE panel (Part B)",
        "executionType": "Single",
        "rationale": "The protocol introduces additional time points for this panel throughout the Part B extension."
      },
      {
        "activityId": "Immunogenicity assessment (Part A)",
        "executionType": "Single",
        "rationale": "Evaluated as a secondary exploratory objective involving multiple collection time points throughout the study phase."
      },
      {
        "activityId": "Home infusion administration",
        "executionType": "Single",
        "rationale": "Study drug administration is a repeated activity throughout the treatment duration."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. The 6-week Screening/Observation Period may be extended by 1 week for patients requiring a blood transfusion prior to study drug administration.",
        "footnoteId": "fn_1",
        "sourceText": "a. The 6-week Screening/Observation Period may be extended by 1 week for patients requiring a blood "
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. Patients should return to the site 9 weeks after last dose for ET procedures, EOS assessment, or Safety Follow-up procedures upon completion of dosing in the study.",
        "footnoteId": "fn_2",
        "sourceText": "b. Patients should return to the site 9 weeks after last dose for ET procedures, EOS assessment, or "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. Applicable to patients who do not have documented vaccination against encapsulated bacterial pathogens within 5 years of enrollment.",
        "footnoteId": "fn_3",
        "sourceText": "c. Applicable to patients who do not have documented vaccination against encapsulated bacterial path"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Prior bone marrow biopsy report review, prior tissue assessment, or new bone marrow biopsy (as applicable).",
        "footnoteId": "fn_4",
        "sourceText": "d. Prior bone marrow biopsy report review, prior tissue assessment, or new bone marrow biopsy (as ap"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_at",
        "text": "e. Females of child-bearing potential only. Serum pregnancy test to be performed at Screening. Serum or urine pregnancy test to be performed on Days 0, 21, 49, 77, 105, 133, and 161, and at Week 26/EOT or at the ET Visit.",
        "footnoteId": "fn_5",
        "sourceText": "e. Females of child-bearing potential only. Serum pregnancy test to be performed at Screening. Serum"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. Height measured at Screening only. Body weight measured every 3 months during Part B.",
        "footnoteId": "fn_6",
        "sourceText": "f. Height measured at Screening only. Body weight measured every 3 months during Part B."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "g. Vital signs measurements (supine BP, PR, RR, and oral temperature) are to be obtained at Screening and at each subsequent visit.",
        "footnoteId": "fn_7",
        "sourceText": "g. Vital signs measurements (supine BP, PR, RR, and oral temperature) are to be obtained at Screenin"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. For a complete list of analytes, see protocol (Section 10.1, Appendix A).",
        "footnoteId": "fn_8",
        "sourceText": "h. For a complete list of analytes, see protocol (Section 10.1, Appendix A)."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. BIVV009 doses of 6.5 grams (if <75 kg) or 7.5 grams (if >=75 kg) based on patient's baseline body weight will be administered via IV infusion.",
        "footnoteId": "fn_9",
        "sourceText": "i. BIVV009 doses of 6.5 grams (if <75 kg) or 7.5 grams (if >=75 kg) based on patient's baseline body"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. During Part A, PK and PD samples will be collected at predose and 1 hour (+/-15 minutes) postdose.",
        "footnoteId": "fn_10",
        "sourceText": "j. During Part A, PK and PD samples will be collected at predose and 1 hour (+/-15 minutes) postdose"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_after",
        "text": "k. AEs will be recorded from the time the patient signs the informed consent form until 9 weeks after administration of the last dose of study drug.",
        "footnoteId": "fn_11",
        "sourceText": "k. AEs will be recorded from the time the patient signs the informed consent form until 9 weeks afte"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. To be performed every 3 months.",
        "footnoteId": "fn_12",
        "sourceText": "l. To be performed every 3 months."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "m. Refer to the Laboratory Manual for details of sample collection during Screening.",
        "footnoteId": "fn_13",
        "sourceText": "m. Refer to the Laboratory Manual for details of sample collection during Screening."
      },
      {
        "id": "fn_cond_14",
        "conditionType": "timing_at",
        "text": "n. Samples will be collected for a subset of the disease-related biomarkers at Day 91 only.",
        "footnoteId": "fn_14",
        "sourceText": "n. Samples will be collected for a subset of the disease-related biomarkers at Day 91 only."
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o. During Part B, a 12-lead ECG will be conducting pre- and postdose at 3 months (Day 273).",
        "footnoteId": "fn_15",
        "sourceText": "o. During Part B, a 12-lead ECG will be conducting pre- and postdose at 3 months (Day 273)."
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "p. During Part B, the healthcare resource utilization data will be recorded every 4 weeks.",
        "footnoteId": "fn_16",
        "sourceText": "p. During Part B, the healthcare resource utilization data will be recorded every 4 weeks."
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "q. To be performed in the following order: FACIT-Fatigue first, PGIS second, PGIC third, SF-12 fourth, and EQ-5D-5L fifth.",
        "footnoteId": "fn_17",
        "sourceText": "q. To be performed in the following order: FACIT-Fatigue first, PGIS second, PGIC third, SF-12 fourt"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "r. During Part B, ADA samples will be collected at predose at 3-month intervals during the 1st year of treatment in Part B.",
        "footnoteId": "fn_18",
        "sourceText": "r. During Part B, ADA samples will be collected at predose at 3-month intervals during the 1st year "
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "s. SLE panel will be performed every 6 months in Part-B of the study.",
        "footnoteId": "fn_19",
        "sourceText": "s. SLE panel will be performed every 6 months in Part-B of the study."
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_after",
        "text": "t. In Part B, hematology and clinical chemistry panels to be performed every 2 weeks after Week 25 and up to Week 79.",
        "footnoteId": "fn_20",
        "sourceText": "t. In Part B, hematology and clinical chemistry panels to be performed every 2 weeks after Week 25 a"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "sequence",
        "text": "u. To be performed at 3-month intervals during the 1st year of treatment in Part B, and then at 6-month intervals.",
        "footnoteId": "fn_21",
        "sourceText": "u. To be performed at 3-month intervals during the 1st year of treatment in Part B, and then at 6-mo"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Efficacy Response (Part A)",
        "endpointType": "Primary",
        "inputs": [
          "Hb",
          "transfusion_history",
          "lactate_dehydrogenase"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 26",
          "duration": "P26W"
        },
        "algorithm": "(Hb_increase >= 1.5 g/dL OR Hb_normalization) AND (no_transfusions_from_week_5_to_26) AND (no_prohibited_medications)",
        "successCriteria": "Composite of Hb increase ≥ 1.5 g/dL from baseline, transfusion-free status, and no prohibited medications",
        "sourceText": "The primary endpoint is a composite endpoint of the following: Increase in Hb ≥ 1.5 g/dL from baseline at the treatment assessment visit (Week 26), no blood transfusion from Week 5 through Week 26, an"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Immunogenicity of BIVV009",
        "endpointType": "Secondary",
        "inputs": [
          "ADA_sample"
        ],
        "timeWindow": {
          "reference": "Part B treatment",
          "duration": "P2Y"
        },
        "algorithm": "Presence of Anti-Drug Antibodies (ADA) at 3-month intervals (Year 1) then 6-month intervals",
        "successCriteria": "Characterization of immunogenicity profile over 2 years",
        "sourceText": "Secondary Exploratory Objective for Part A was added: To evaluate the immunogenicity of BIVV009... Collection of ADA samples during the 1st year of treatment in part B, then every 6 months."
      },
      {
        "id": "ep_3",
        "name": "Exploratory: Home Infusion Satisfaction",
        "endpointType": "Exploratory",
        "inputs": [
          "satisfaction_survey_score"
        ],
        "timeWindow": {
          "reference": "First and fourth home infusion",
          "duration": "P4-infusions"
        },
        "algorithm": "Assessment of satisfaction scores after 1st and 4th home infusions",
        "successCriteria": "Completion of satisfaction assessment in patients receiving home infusion",
        "sourceText": "Part B Satisfaction with home infusion after first home infusion and after four home infusion will be assessed in patients with home infusion was added."
      },
      {
        "id": "ep_4",
        "name": "Safety: Home Infusion Adverse Events",
        "endpointType": "Secondary",
        "inputs": [
          "AE_onset_time",
          "infusion_time"
        ],
        "timeWindow": {
          "reference": "home infusion",
          "duration": "PT24H"
        },
        "algorithm": "AE_onset_time - infusion_time <= 24 hours",
        "successCriteria": "Identification of AEs occurring within 24 hours of home administration",
        "sourceText": "For patients with home infusions, safety assessments include AEs with onset within 24 hours of infusion was added."
      },
      {
        "id": "ep_5",
        "name": "Pharmacokinetics (PK) and Pharmacodynamics (PD)",
        "endpointType": "Secondary",
        "inputs": [
          "PK_concentration",
          "PD_marker"
        ],
        "timeWindow": {
          "reference": "dose administration",
          "duration": "PT1H15M"
        },
        "algorithm": "Measurement at predose and 1 hour (±15 minutes) postdose",
        "successCriteria": "Successful collection of samples at 3-month (Year 1) and 6-month intervals",
        "sourceText": "Collection of PK samples at predose and 1 hour (±15 minutes) postdose was added. Samples will be collected at 3-month intervals during the 1st year of treatment in Part B and then at 6-month intervals"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from Baseline in Hemoglobin",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Hemoglobin"
        ],
        "derivationRule": "post_baseline_value - baseline_value",
        "baselineDefinition": "Last non-missing value prior to the first dose of BIVV009",
        "baselineVisit": "Day 1",
        "analysisWindow": "As specified in the Statistical Analysis Plan (SAP)",
        "imputationRule": "Not specified in provided text",
        "unit": "g/dL"
      },
      {
        "id": "dv_2",
        "name": "Fixed Dose Assignment",
        "variableType": "Categorical",
        "sourceVariables": [
          "Body Weight"
        ],
        "derivationRule": "If weight < 75 kg then dose = 6.5 g; If weight >= 75 kg then dose = 7.5 g",
        "baselineDefinition": "Weight measured at Screening/Baseline",
        "baselineVisit": "Day 1",
        "analysisWindow": "Treatment Period",
        "imputationRule": "None",
        "unit": "g"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening/observation period",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening/observation period",
        "Baseline",
        "Part A",
        "Part B Extension phase",
        "ET/EOS/Safety follow-up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening/observation period",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Part A",
          "trigger": "Progress to Part A"
        },
        {
          "fromState": "Part A",
          "toState": "Part B Extension phase",
          "trigger": "Progress to Part B Extension phase"
        },
        {
          "fromState": "Part B Extension phase",
          "toState": "ET/EOS/Safety follow-up",
          "trigger": "Progress to ET/EOS/Safety follow-up"
        },
        {
          "fromState": "Screening/observation period",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening/observation period": "epoch_1",
        "Baseline": "epoch_2",
        "Part A": "epoch_3",
        "Part B Extension phase": "epoch_4",
        "ET/EOS/Safety follow-up": "epoch_5",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Trial Protocol",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "g"
          },
          {
            "amount": 4.0,
            "unit": "g"
          },
          {
            "amount": 5.0,
            "unit": "g"
          }
        ],
        "sourceText": "Protocol 06 Page 2 of 99 Bioverativ USA Inc. Confidential PROTOCOL AMENDMENT SUMMARY OF CHANGES DOCUMENT HISTORY Document Country/Countries impacted by amendment Date Amended Clinical Trial Protocol 0"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Protocol Version",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "g"
          },
          {
            "amount": 3.0,
            "unit": "g"
          },
          {
            "amount": 4.0,
            "unit": "g"
          },
          {
            "amount": 6.0,
            "unit": "g"
          }
        ],
        "sourceText": "ial PROTOCOL AMENDMENT SUMMARY OF CHANGES DOCUMENT HISTORY Document Country/Countries impacted by amendment Date Amended Clinical Trial Protocol 06 Global 19 December 2019 Clinical Study Protocol Vers"
      },
      {
        "id": "dosing_3",
        "treatmentName": "BIVV009 is",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 180.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "26 weeks",
        "sourceText": "ffects from exaggerated pharmacology (ie, autoimmune diseases, bacterial infections) were observed in those studies. As a result, the no observed adverse effect (dose) level (NOAEL) established for BI"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "BIVV009",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Part A (duration not specified in snippet) followed by Part B (2 years)",
        "doseModifications": [
          "Home infusion facilities provided for specific countries in Part B"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Section 6.1.1.1: Screening Assessments (initiating at Day -42)"
      },
      {
        "id": "visit_1",
        "visitName": "Visit 009",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "BIVV009-03 Cardinal Amended Clinical Trial Protocol 06 Page 5 of 99"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Follow-up",
        "sourceText": "following completion of LPO in Part A. The change was made to gather more evidence on long-term safety, tolerability"
      },
      {
        "id": "visit_7",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "early termination/end of study/safety follow-up was renumbered as 6.1.7. This change was made to evaluate the"
      },
      {
        "id": "visit_11",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "EOT end of treatment EQ-5D-5L"
      },
      {
        "id": "visit_12",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "baseline visit (and first infusion of study drug) must occur at least 7 days following the transfusion. Part A"
      },
      {
        "id": "visit_19",
        "visitName": "Visit 9",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "Follow up visit 9 weeks after last dose. Samples will also be collected if a patient experiences a hematologic breakthrough or withdraws from the study. SAMPLE SIZE:"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Part B Extension Phase (Bi-weekly)",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Part B Extension Phase"
      },
      {
        "id": "visit_10",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "Randomization ............................................................................................................................... 54 6.2.4 Dose preparation and administration ............."
      },
      {
        "id": "visit_4",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Part A",
        "sourceText": "points Day 7, 35, 77, 133 and 175, may be used to assay ADA was added. This change was made to help characterize"
      },
      {
        "id": "visit_16",
        "visitName": "Week 5",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 5,
        "sourceText": "transfusion from Week 5 through Week 26 (EOT) and did not receive treatment for CAgD beyond what is permitted per protocol. Additionally, the patient’s Hgb level must meet either of the following crit"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Day 35",
        "targetDay": 35,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": 5,
        "epoch": "Part A"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Day 77",
        "targetDay": 77,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 11,
        "epoch": "Part A"
      },
      {
        "id": "visit_22",
        "visitName": "Day 91",
        "targetDay": 91,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "(Day 91 only) Xo"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Day 133",
        "targetDay": 133,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 19,
        "epoch": "Part A"
      },
      {
        "id": "visit_18",
        "visitName": "Week 23",
        "targetDay": 155,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 23,
        "sourceText": "Week 23, 25, and 26)  Mean change from baseline in QOL, as assessed by the change in Functional"
      },
      {
        "id": "visit_13",
        "visitName": "Week 25",
        "targetDay": 169,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 17,
        "targetWeek": 25,
        "sourceText": "60 minutes on Day 0, Day 7, and every 14 days thereafter through Week 25 (ie, Days 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, and 175). Patients who miss a dose (ie, outside the dosing window or"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Day 175",
        "targetDay": 175,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 25,
        "epoch": "Part A"
      },
      {
        "id": "visit_5",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 26,
        "sourceText": "(Week 26) ADA: In patients who consented to the use of their blood samples for future research, PD"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 1",
        "targetDay": 182,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 26,
        "epoch": "Part A",
        "sourceText": "visit 1 week prior to the next scheduled dose in order to receive an additional loading dose. Patients will have an End-of-Treatment (EOT) visit in Part A on Day 182 (Week 26). Patients who meet the t"
      },
      {
        "id": "visit_17",
        "visitName": "Week 27",
        "targetDay": 183,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "targetWeek": 27,
        "sourceText": "Bi-weekly dosing starting at Week 27 and continuing for 2 years after LPO in Part A"
      },
      {
        "id": "visit_20",
        "visitName": "Week 41",
        "targetDay": 281,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 41,
        "sourceText": "qualified by the Investigator and no sooner than after Week 41 (Day 287) and without evidence of intolerance of the study drug as determined by the Investigator. No new risks related to home infusions"
      },
      {
        "id": "visit_21",
        "visitName": "Day 287",
        "targetDay": 287,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 23,
        "sourceText": "qualified by the Investigator and no sooner than after Week 41 (Day 287) and without evidence of intolerance of the study drug as determined by the Investigator. No new risks related to home infusions"
      },
      {
        "id": "visit_8",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 24,
        "sourceText": "early termination/end of study/safety follow-up was renumbered as 6.1.7. This change was made to evaluate the"
      },
      {
        "id": "visit_6",
        "visitName": "Week 79",
        "targetDay": 547,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 25,
        "targetWeek": 79,
        "epoch": "Part B Extension Phase",
        "sourceText": "week 79. This change was made to reflect the study assessments frequency in the 2nd year of"
      }
    ]
  }
}